207 related articles for article (PubMed ID: 33148692)
21. Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection.
Albers JJ; Ammon T; Gosmann D; Audehm S; Thoene S; Winter C; Secci R; Wolf A; Stelzl A; Steiger K; Ruland J; Bassermann F; Kupatt C; Anton M; Krackhardt AM
Life Sci Alliance; 2019 Apr; 2(2):. PubMed ID: 30877233
[TBL] [Abstract][Full Text] [Related]
22. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
23. Efficient Non-Viral T-Cell Engineering by Sleeping Beauty Minicircles Diminishing DNA Toxicity and miRNAs Silencing the Endogenous T-Cell Receptors.
Clauss J; Obenaus M; Miskey C; Ivics Z; Izsvák Z; Uckert W; Bunse M
Hum Gene Ther; 2018 May; 29(5):569-584. PubMed ID: 29562762
[TBL] [Abstract][Full Text] [Related]
24. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
Tzannou I; Papadopoulou A; Naik S; Leung K; Martinez CA; Ramos CA; Carrum G; Sasa G; Lulla P; Watanabe A; Kuvalekar M; Gee AP; Wu MF; Liu H; Grilley BJ; Krance RA; Gottschalk S; Brenner MK; Rooney CM; Heslop HE; Leen AM; Omer B
J Clin Oncol; 2017 Nov; 35(31):3547-3557. PubMed ID: 28783452
[TBL] [Abstract][Full Text] [Related]
25. Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies.
Quach DH; Lulla P; Rooney CM
Blood; 2023 Feb; 141(8):877-885. PubMed ID: 36574622
[TBL] [Abstract][Full Text] [Related]
26. Extracellular domains of CD8α and CD8ß subunits are sufficient for HLA class I restricted helper functions of TCR-engineered CD4(+) T cells.
van Loenen MM; Hagedoorn RS; de Boer R; Falkenburg JH; Heemskerk MH
PLoS One; 2013; 8(5):e65212. PubMed ID: 23738014
[TBL] [Abstract][Full Text] [Related]
27. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
29. Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.
Blaeschke F; Thiel U; Kirschner A; Thiede M; Rubio RA; Schirmer D; Kirchner T; Richter GHS; Mall S; Klar R; Riddell S; Busch DH; Krackhardt A; Grunewald TG; Burdach S
Oncotarget; 2016 Jul; 7(28):43267-43280. PubMed ID: 27281613
[TBL] [Abstract][Full Text] [Related]
30. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
31. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
Sun L; Guo H; Jiang R; Lu L; Liu T; He X
Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
[TBL] [Abstract][Full Text] [Related]
32. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
[TBL] [Abstract][Full Text] [Related]
33. T-Cell Therapeutics Targeting Human Parainfluenza Virus 3 Are Broadly Epitope Specific and Are Cross Reactive With Human Parainfluenza Virus 1.
Harris KM; Horn SE; Grant ML; Lang H; Sani G; Jensen-Wachspress MA; Kankate VV; Datar A; Lazarski CA; Bollard CM; Keller MD
Front Immunol; 2020; 11():575977. PubMed ID: 33123159
[TBL] [Abstract][Full Text] [Related]
34. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.
Soon CF; Behrendt P; Todt D; Manns MP; Wedemeyer H; Sällberg Chen M; Cornberg M
J Hepatol; 2019 Oct; 71(4):673-684. PubMed ID: 31203151
[TBL] [Abstract][Full Text] [Related]
35. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
Erickson TA; Shih YP; Fass J; Jang M; Tran E
Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
[No Abstract] [Full Text] [Related]
36. Hematopoietic stem cells for cancer immunotherapy.
Gschweng E; De Oliveira S; Kohn DB
Immunol Rev; 2014 Jan; 257(1):237-49. PubMed ID: 24329801
[TBL] [Abstract][Full Text] [Related]
37. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.
Stief TA; Kaeuferle T; Müller TR; Döring M; Jablonowski LM; Schober K; Feucht J; Dennehy KM; Willier S; Blaeschke F; Handgretinger R; Lang P; Busch DH; Feuchtinger T
Mol Ther; 2022 Jan; 30(1):198-208. PubMed ID: 34058386
[TBL] [Abstract][Full Text] [Related]
38. Cbl-b regulates antigen-induced TCR down-regulation and IFN-gamma production by effector CD8 T cells without affecting functional avidity.
Shamim M; Nanjappa SG; Singh A; Plisch EH; LeBlanc SE; Walent J; Svaren J; Seroogy C; Suresh M
J Immunol; 2007 Dec; 179(11):7233-43. PubMed ID: 18025165
[TBL] [Abstract][Full Text] [Related]
39. Production of interferon-gamma by activated T-cell receptor-alphabeta CD8alphabeta intestinal intraepithelial lymphocytes is required and sufficient for disruption of the intestinal barrier integrity.
Zufferey C; Erhart D; Saurer L; Mueller C
Immunology; 2009 Nov; 128(3):351-9. PubMed ID: 20067535
[TBL] [Abstract][Full Text] [Related]
40. Simple and efficient generation of virus-specific T cells for adoptive therapy using anti-4-1BB antibody.
Imahashi N; Nishida T; Goto T; Terakura S; Watanabe K; Hanajiri R; Sakemura R; Imai M; Kiyoi H; Naoe T; Murata M
J Immunother; 2015; 38(2):62-70. PubMed ID: 25658615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
